when the leading statement from the CEO is "The excellent safety profile of Xanamem was again demonstrated” it’s time to run.
- Forums
- ASX - By Stock
- ACW
- Ann: ACW XanaCIDD phase 2a trial topline results
Ann: ACW XanaCIDD phase 2a trial topline results, page-101
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
2.9¢ |
Change
-0.002(6.45%) |
Mkt cap ! $78.63M |
Open | High | Low | Value | Volume |
3.0¢ | 3.1¢ | 2.9¢ | $181.2K | 6.113M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 3307701 | 2.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.0¢ | 1238266 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 3297701 | 0.029 |
9 | 1013680 | 0.028 |
10 | 692037 | 0.027 |
13 | 3261088 | 0.026 |
19 | 3687643 | 0.025 |
Price($) | Vol. | No. |
---|---|---|
0.030 | 1238266 | 8 |
0.031 | 2477817 | 9 |
0.032 | 2127719 | 10 |
0.033 | 2291237 | 11 |
0.034 | 723084 | 6 |
Last trade - 10.53am 13/08/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online